# TongliBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tonglibio

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.tonglibio.com
- Total disclosed funding: $1.4M
- Latest round: Angel (Apr 8, 2017)
- Investors on record: 1

## About

Established in 2012 and based in Suzhou, China, TongliBio is a biotechnology company that provides drugs for zoonotic infectious diseases. In September 2020, the firm closed a strategic investment. Mingxin Qian, the founder of the company, has worked in Bristol-Myers Squibb, Genentech and other companies.

The company focuses on the development of anthelmintic drugs for tropical infectious diseases and zoonosis. Its products include TL-010, TL-230 and TL-310.

## Funding rounds

- Angel, Apr 8, 2017, $1.4M — TF Capital

## Investors

- TF Capital — Angel